Compare Edwards Lifesciences Corporation Common Stock (EW) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Johnson & Johnson — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while Johnson & Johnson trades at $256.46 (market cap $622.84B). The key difference: Johnson & Johnson is far larger — about 12.6× Edwards Lifesciences Corporation Common Stock's market cap, and Johnson & Johnson pays a 2.07% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | JNJ | |
|---|---|---|
Market Cap | $49.44B | $622.84B |
Volume | 3,508,027 | 5,277,426 |
Sector | Health | Health |
52-Week High | $95.18 | $278.43 |
52-Week Low | $72.65 | $186.00 |
Enterprise Value | $45.90B | $651.12B |
Typical Hold Time | — | 129 Days |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% today, with a bearish technical signal but strong fundamentals including a 21.48% net income margin and consistent earnings beats. The stock is supported by a diversified healthcare portfolio and a recent dividend declaration of $1.34 payable in September 2026. Revenue growth is projected to reach $97.9B in 2026, though net income is expected to moderate. Analyst consensus is bullish with a $286.53 price target, but technical indicators show resistance near $260.
JNJ presents a solid long-term investment opportunity due to its robust profitability, high ROE of 25.74%, and defensive sector positioning. Risks include increasing debt-to-asset ratio (24.06% in 2025) and competitive pressures in pharmaceuticals. The stock's current valuation at a P/E of 29.98 may limit near-term upside, but analyst optimism and dividend reliability support a positive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
